Exploring Three SEHK Growth Companies With High Insider Ownership

In This Article:

Amid a backdrop of global economic fluctuations, the Hong Kong market has shown resilience, with the Hang Seng Index recently experiencing a notable uptick. This positive momentum underscores the potential value of investing in growth companies within this market, particularly those with high insider ownership which often signals strong confidence in the company's future from those who know it best.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name

Insider Ownership

Earnings Growth

iDreamSky Technology Holdings (SEHK:1119)

20.1%

104.1%

New Horizon Health (SEHK:6606)

16.6%

61%

Meitu (SEHK:1357)

38%

34.3%

Adicon Holdings (SEHK:9860)

22.3%

29.6%

DPC Dash (SEHK:1405)

38.2%

91.5%

Tian Tu Capital (SEHK:1973)

34%

70.5%

Zhejiang Leapmotor Technology (SEHK:9863)

14.2%

74%

Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)

15.7%

100.1%

Ocumension Therapeutics (SEHK:1477)

17.7%

93.7%

Beijing Airdoc Technology (SEHK:2251)

26.4%

83.9%

Click here to see the full list of 52 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

Kingdee International Software Group

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kingdee International Software Group Company Limited operates as an investment holding company specializing in enterprise resource planning, with a market capitalization of approximately HK$32.87 billion.

Operations: The company generates revenue primarily from two segments: Cloud Service Business, which contributes approximately CN¥4.50 billion, and ERP Business, adding around CN¥1.17 billion.

Insider Ownership: 19.7%

Earnings Growth Forecast: 46.1% p.a.

Kingdee International Software Group is poised for notable growth, with revenue expected to increase by 14.3% annually, outpacing the Hong Kong market's 8.1%. Although its return on equity is projected at a modest 6.2%, analysts are optimistic about a substantial price increase of 50.7%. The company has recently amended its articles of association, signaling strategic adjustments possibly linked to its focus on subscription and AI-driven services, which anticipate a revenue CAGR of 15% to 20% over the next three years.

SEHK:268 Ownership Breakdown as at May 2024

CanSino Biologics

Simply Wall St Growth Rating: ★★★★★☆

Overview: CanSino Biologics Inc. is a company based in the People's Republic of China that focuses on developing, manufacturing, and commercializing vaccines, with a market capitalization of approximately HK$9.34 billion.